Schulof. R S RS; Simon. G L GL; Sztein. M B MB; Parenti. D M DM; DiGioia. R A RA; Courtless. J W JW;...
In a small early‑stage trial, daily injections of a thymosin mixture (TF5) at 60 mg helped restore a specific immune test (MLR) in a few people with advanced HIV‑like infection, without serious side effects except occasional skin irritation. The single‑dose thymosin‑alpha‑1 didn’t show benefits, and overall the treatment didn’t change key virus‑related markers or prevent disease in most participants.
In a small ICU trial, giving the immune‑boosting peptide thymosin‑alpha‑1 (1.6 mg under the skin each day for a week) helped improve immune cell numbers and reduced severity scores in patients with severe sepsis, especially when combined with continuous blood‑purification treatments.
Adding the peptide thymopentin (TP5) to the usual hepatitis B drugs (entecavir and pegylated interferon) was safe and seemed to speed up the drop in the hepatitis B surface antigen in some patients, especially those who already had low levels of the antigen. In lab cells, TP5 worked together with interferon to cut down the virus's hidden DNA form.
Poo. Jorge L JL; Sánchez Avila. Francisco F; Kershenobich. David D; García Samper. Xochitl...
In a small open‑label trial, adding the peptide thymosin‑alpha‑1 (thymalfasin) to the standard hepatitis C drugs peginterferon‑alpha‑2a and ribavirin helped about half of the participants clear the virus during treatment, and roughly one‑fifth kept the virus cleared after 24 weeks off therapy. The peptide was well tolerated and didn’t need dose cuts.
Adding the immune‑boosting peptide thymosin‑alpha‑1 after liver cancer surgery, together with a standard chemo‑embolization treatment, didn’t cut the chance of the cancer coming back, but it seemed to push the relapse back by a few months and helped patients live a bit longer.
The study used electron microscopy to watch how the receptors for insulin and the peptide thymosin‑alpha‑1 first attach to their cells and start to be pulled inside. It found that the very early steps look a lot alike for both hormones, but there are some subtle differences in how the receptor spots group together and begin internalizing.
Vahouny. G V GV; Kyeyune-Nyombi. E E; McGillis. J P JP; Tare. N S NS; Huang. K Y KY; Tombes. R R; Go...
The study found that thymosin-alpha-1 and related thymosin peptides do NOT directly cause rat adrenal cells to make more steroid hormones in a dish, and they don't boost the cells' response to ACTH. Any steroid increase seen in living animals is probably due to brain signals, not a direct adrenal effect.
Shurlygina. A A; Litvinenko. G G; Dergacheva. T T; Trufakin. V V
The study shows that women with inflammatory gynecologic problems have different amounts of the immune‑modulating peptide thymosin‑alpha‑1 in their blood, and those levels change throughout the day. The pattern depends on what kind of inflammation they have and how well their treatment works, suggesting both the amount and timing of thymosin‑alpha‑1 matter for immune regulation.
Scientists made two slightly altered versions of the immune‑boosting peptide thymosin‑alpha‑1 and tested them on kidney‑failure patients with weak immune cells. The version that had a fluorine atom added (a fluorinated phenylalanine at position 21) helped the patients' immune cells recover better than the non‑fluorinated version, which performed about the same as the original peptide.
Ho. A D AD; Ma. D D DD; Price. G G; Hunstein. W W; Hoffbrand. A V AV
The study shows that thymosin‑alpha‑1 can push immature human T‑cells toward a more mature state in lab dishes, changing several enzyme activities and increasing a marker (OKT3) of mature T‑cells. It also works a bit differently in cancerous T‑cell lines.
Zhou. Jing J; Mao. Wenjian W; Ke. Lu L; Chen. Tao T; He. Wenhua W; Pan. Xinting X; Chen. Miao M; He....
Researchers are testing whether the immune‑boosting peptide thymosin‑alpha‑1 can lower the chance of infected pancreatic tissue in people with severe pancreatitis, but the study is still just a plan – no results are available yet.
Nevo. Nadav N; Lee Goldstein. Adam A; Bar-David. Shoshi S; Natanson. Maya M; Alon. Gilad G; Lahat. G...
In a mouse study, adding the immune‑boosting peptide thymosin‑alpha‑1 to a heated chemotherapy wash (HIPEC) for colon cancer spread helped the mice live longer, but the peptide didn’t directly kill tumor cells—it worked by turning on a specific type of immune response.
Gu. Bin B; Zhou. Yu Y; Nie. Yao Y; Wang. Luhao L; Liang. Liqun L; Liao. Zihuai Z; Wen. Jingyi J; Gua...
Thymosin‑alpha‑1 might lower death rates in people with severe infections (sepsis), but the evidence is mixed and the studies aren’t big enough to be sure. The benefit seems to vary by health condition, and the data aren’t strong enough to change everyday health routines.
Yu. Jiamin J; Yin. Li L; Guo. Wenjie W; Wang. Qiang Q; Liu. Juying J; Zhang. Lansheng L; Ye. Hongxun...
A small Phase II trial tested a mix of radiation, a PD‑1 cancer drug, GM‑CSF, and the peptide thymosin‑alpha‑1 in people with advanced cancers. About a quarter of patients saw tumor shrinkage and many had disease stabilization, with some showing distant tumor shrinkage (abscopal effect). Side effects were mostly mild to moderate, with a few serious events. The results are promising for cancer treatment but don’t give clear guidance for healthy individuals looking to boost immunity or longevity.
The abstract explains that cystic fibrosis is caused by a faulty CFTR gene, leading to thick mucus and lung problems. Researchers are trying gene therapy and other methods to fix the ion channel issue, and they mention thymosin‑alpha‑1 as a possible molecule that could help correct the defect, but no clear protocol or dosage is given.
In a large group of stem‑cell transplant patients, only a few got a serious adenovirus infection that was found using DNA sequencing. The infection hit multiple organs and was usually fatal, even with antiviral drugs and immune‑boosting treatments. One patient also received thymosin‑α1, but it didn’t clearly change the outcome.
Ke. Lu L; Zhou. Jing J; Mao. Wenjian W; Chen. Tao T; Zhu. Yin Y; Pan. Xinting X; Mei. Hong H; Singh....
A big study gave patients with severe pancreatitis a drug called thymosin‑alpha‑1 to see if it would lower a dangerous infection in the pancreas. The drug didn’t cut the infection rate or improve other serious complications compared to a placebo, so it didn’t show any real benefit in this setting.
This review looked at studies where a drug called ulinastatin, sometimes mixed with the peptide thymosin‑alpha‑1, was used to treat people with severe infections (sepsis). It pooled results from several meta‑analyses to see if these combos helped patients live longer, need less time on a ventilator, or spend less time in the ICU. The data are mixed and mainly apply to sick hospital patients, not healthy individuals looking to boost longevity or performance.
This study is a planned clinical trial that will test whether adding thymosin‑alpha‑1 (thymalfasin) to a combo of radiotherapy, a PD‑1/PD‑L1 cancer drug, and GM‑CSF can improve outcomes for people with hard‑to‑treat solid tumors. It’s still just a protocol—no results yet—so it doesn’t give any concrete tips you can use right now.
This study tested a cancer treatment that combined precise radiation, weekly chemo, and a small dose of the peptide thymosin‑alpha‑1 in patients with hard‑to‑treat thymus tumors. The regimen showed good tumor shrinkage and survival, with very low rates of serious lung inflammation, and the peptide might have helped protect the lungs and keep quality of life stable. However, the findings are specific to cancer patients and not directly useful for everyday health‑hacking or longevity goals.